Home  /  Resource Library  /  Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton’S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton’S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

ASH: Results of a study investigating Vecabrutinib for treatment of certain relapsed B-cell lymphomas.